INTEREST
Meeting category
Date(s)
24 Nov 2020 - 4 Dec 2020
Meeting type
Virtual

INTEREST 2020

Related Enduring Materials

Enduring Materials
Session 1 - Opening -
Impact of COVID-19 on HIV, Tuberculosis, and Malaria Epidemiology and Treatment Services Across Africa
John Nkengasong, PhD
U.S. President's Emergency Plan for AIDS Relief (PEPFAR), United States
HIV and Climate Change: the Research Opportunities
Matthew Chersich, MBBCh, MSc, PhD
University of the Witwatersrand, South Africa
Q&A - Session 1 - Opening
Oral Abstract Presentations 1 -
The Effect of Hazardous Drinking on Key HIV Outcomes among HIV-Positive Men: Results from Six Population-Based HIV Impact Assessments Completed in Sub-Saharan Africa (2015-2018)
Gregory Chang
#3
The Frequency and Yield of Cryptococcal Antigen Screening among Newly Diagnosed and Anti-Retroviral Therapy Experienced HIV Patients in Rural Uganda
Joseph Baluku
#4
Cost-Utility Analysis of Dolutegravir-Versus Efavirenz 400mg- Based Regimen for the Initial Treatment of HIV-Infected Patients in Cameroon: 96-week Results from the NAMSAL ANRS 12313 Trial
Marwan al Qays Bousmah
#2
What Shapes Resilience Among People Living with HIV? A Multi- Country Analysis of Data from the PLHIV Stigma Index 2.0
Stella Kentusi
#1
Q&A - Oral Abstract Presentations 1

Day 2 - Tuesday, 1 December 2020

-
Session 2 -HIV Prevention
Nyaradzo Mavis Mgodi, MBChB, MMed
University of Zimbabwe Clinical Trials Research Centre, Zimbabwe
The ECHO Trial: What’s Next on Contraception and HIV: Policy, Practice, and Research?
Margaret Phiri Kasaro, MBChB, MSc
University of North Carolina Global Project Zambia (UNC GPZ), Zambia
Q&A - Session 2 - HIV Prevention
Mini-Oral Abstract Presentations 1 -
Striving Towards HIV Epidemic Control through Reaching a Population in Correctional Facilities in Namibia
Hilaria Ashivudhi
#26
Index-Linked HIV Testing for Children and Adolescents in Health Facility and Community-Based Settings in Zimbabwe: Findings from the B-GAP Study
Chido Dziva Chikwari
#24
Perceptions,Preferences and Access to Community-Based HIV Testing Services among Men who have Sex with Men (MSM) in Côte d’Ivoire
Maxime Inghels
#23
It is Better if you are Going to Test Yourself…”: Attitudes, Test Preferences and Challenges of HIV Self-Testing among Female Sex Workers in eThekwini, South Africa: the Siyaphanta study
Kedibone Sithole
#33
Traditional Healers Can Increase Uptake of HIV Testing among Adults of Unknown Serostatus: Results from a Cluster Randomized Pilot Study in Southwestern Uganda
Radhika Sundararajan
#37
A Gap Analysis and Total Quality Leadership and Accountability Intervention Triples HIV Testing Yield among Key Population in Zambia
Florence Tembo Mulenga
#18
Gaining Traction: Promising Shifts in Gender Norms and Intimate Partner Violence During an HIV prevention Trial in South Africa
Ann Gottert
#13
Case Series of Urethrocutaneous Fistulas After Voluntary Medical Male Circumcision for HIV Prevention—15 African Countries, 2015– 2019
Todd Lucas
#34
Is the Use of Creatinine Clearance Test at Baseline for PrEP Enrolment Necessary in Resource-Constrained Settings?
David Chilongozi
#15
Q&A - Mini-Oral Abstract Presentations 1

Day 3 - Wednesday, 2 December 2020

Oral Abstract Presentations 2 -
Monitoring and Management of Treatment Failure Among People on Antiretroviral Therapy in Mozambique: Lessons Learned to Improve Treatment Effectiveness
Laura Marcela Torres
#6
Rapid Antiretroviral Therapy Initiation and the Risk of Mortality and Loss to Follow-Up in Children with HIV
Peter James Elyanu
#7
High Levels of HIV Drug Resistance in Adult Patients with Unsuppressed Viral Load, Measured Through Routine Viral Load Programme Monitoring in South Africa, 2019
Gillian Hunt
#5
Effect of Same-Day ART Initiation on Early Retention in Rakai, Uganda
Jesca Basiima
#8
Q&A - Oral Abstract Presentations 2

Day 4 - Thursday, 3 December 2020

Session 3 - Access to Medicines and TB -
What you Need to Know about Public-Health Licensing and Access to Medicines in Africa
Sébastien Morin, PhD
Medicines Patent Pool, Switzerland
TB State-of-the-Art: Implications for Africa
Dereck Tait, MBChB
IAVI, South Africa
Q&A - Session 3 - Access to Medicines and TB
Mini-Oral Abstract Presentations 2 -
Current Approaches for Identifying and Managing HIV Treatment Failure Among Children, Adolescents, and Young People In Sub- Saharan Africa: Multi-Country Experience from the New Horizons Collaborative
Natella Rakhmanina
#36
Syndemic of Hepatitis B and C and Their Coinfection With HIV in Rwanda: Role of Unsafe Medical Practices and Sexual Behaviors
Jean Damascene Makuza
#17
Patient-Reported Outcomes After Direct-Acting Antiviral Treatment for Chronic Hepatitis C in West And Central Africa: The ANRS 12311 TAC Trial
Fabienne Marcellin
#14
Prevalence, Risk and Protective Factors for Common Mental Disorders Among Young People Living With HIV Compared to Their Uninfected Peers From the Kenyan Coast: A Cross Sectional Study
Moses Kachama Nyongesa
#29
Trends in Transmitted Drug Resistance in A Cohort Of ART-Naive HIV- 1 Infected Individuals in Ethiopia
Mulugeta Kiros
#16
Using A Quality Improvement Collaborative Approach to Improve Tuberculosis Prevention Therapy Coverage in The Kavango Region, Namibia
Apollo Basenero
#32
For Each Hour a Patient Living with HIV Spends in the Health Facility, the Probability of Being Retained in Care Decreases: Results from a Patients’ Satisfaction Survey in Mozambique
Caroline De Schacht
#12
Does Navigated Linkage to Care Work? A Cross-Sectional Study of Active Linkage to Care Within an Integrated Non-Communicable Disease
Kathryn Hopkins
#11
Q&A - Mini-Oral Abstract Presentations 2
Session 4 - STI and Implementation Science -
What’s New in Sexually Transmitted Infections and HIV in 2020
Rashida Ferrand, MBBS, FRCP, PhD
London School of Hygiene & Tropical Medicine, United Kingdom / Biomedical Research and Training Institute, Zimbabwe
Implementation Science - an African Perspective
Peter Cherutich, MBChB, PhD, MPH
Ministry of Health, Kenya
Q&A - Session 4 - STI and Implementation Science

Day 5 - Friday, 4 December 2020

Session 5 - Distance Learning and Dolutegravir Controversy -
Engaging in Collaborative Hands-On Learning: Building the Response in Africa
Leonard Bikinesi
Leonard Bikinesi, MD
Ministry of Health and Social Services, Namibia
Dolutegravir and Weight Gain - Where are We?
François Venter, MD, FCP, PhD
Ezintsha, University of the Witwatersrand, South Africa
Q&A - Session 5 - Distance Learning and Dolutegravir Controversy
Mini-Oral Abstract Presentations 3 -
Adverse Event Notification and Tracking Among HIV Positive Patients on ART: Lessons from A Tele-Health Centre In Kampala
Joram Okeng
#10
Creating a Safe Space for Key Populations Within Health Facilities: Experience from Montserrado County, Liberia
Gift Kamanga
#9
Stakeholder Participation in The Establishment of One-Stop Shops and Key Population-Friendly Facilities: Descriptive Lessons from the FHI 360 GF Project
Chidubem Oraelosi
#27
Incident HIV Infection Among Pregnant Women in The South African 2017 Antenatal Survey: Assay-Based Incidence Measurement
Selamawit Woldesenbet
#20
Cost of Antiretroviral Therapy Services Among Patients Who Achieved Viral Suppression: A Case Study Of 9 ART Clinics in Namibia
Ndapewa Hamunime
#31
Alarming Burden of Dual-Class HIV-1 Drug Resistance Among Adolescents Calls for Innovative Antiretroviral Strategies: Baseline Findings from the Ready-Study (EDCTP TMA 1027)
Armanda Nangmo
#25
Positive Effects of Intensified Preventive Calls/Home Visits on Early Retention Among Adults Newly Initiated on Antiretroviral Therapy in Zambézia Province, Mozambique
José Tique
#38
Short-Cycle Therapy in HIV-Infected Adults: 4 days on / 3 days off with Combinations Containing Rilpivirine
Dora Luise
#22
Transcriptional Analysis of Lymph Node Derived Follicular CD4 T Cells Reveal Novel Phenotypic Markers and Functions of T Follicular Regulatory (TFR) Cells
Bongiwe Mahlobo
#21
Q&A - Mini-Oral Abstract Presentations 3
IAS Session - Getting to the Heart of Stigma: What does it take to have an impact at scale?
PRE-WEEK - INTEREST 2020 -
ViiV - Exploring the Basics of Implementation Science in HIV
Grantspersonship NIADS/NIH/Fogarty
Peter Kilmarx, MD, FACP, FIDSA
John E. Fogarty International Center, National Institutes of Health, USA
JIAS - Session: How to write and submit a research manuscript: “publish or perish”
Marlène Bras
JIAS Executive Editor
Ann Grimsrud
JIAS Deputy Editor
Overview
Welcome

The annual INTEREST Conference is the premier scientific conference for HIV in Africa and brings together scientists involved in HIV treatment, pathogenesis, and prevention research from around the world. The conference will showcase cutting-edge knowledge in the diagnosis and treatment of HIV and the prevention of the HIV-1 infection. Additionally, it will continue to foster building a community of African physicians and scientists to facilitate the implementation of local solutions for the management of patients living with HIV-1 infection and for the prevention of HIV transmission.

INTEREST is co-organized by Amsterdam Institute for Global Health and Development (AIGHD) and Virology Education.

Official Conference Website
Click here to visit the official conference website

General Information 

COVID-19 Update
INTEREST 2020 took place from 30 November - 4 December 2020.

The conference was rescheduled from the original dates in May due to the COVID-19 pandemic. We would like to apologise for any inconvenience and take this opportunity to thank you for your ongoing support of the INTEREST conferences. We will continue to monitor the situation closely and will keep you informed. We wish you all safety and health in these unparalleled times.
Past Conferences
2007 – Kampala, Uganda
2008 – Dakar, Senegal
2009 – Lusaka, Zambia
2010 – Maputo, Mozambique
2011 – Dar Es Salaam, Tanzania
2012 – Mombasa, Kenya
2013 – Dakar, Senegal
2014 – Lusaka, Zambia
2015 – Harare, Zimbabwe
2016 – Yaounde, Cameroon
2017 – Lilongwe, Malawi
2018 – Kigali, Rwanda
2019 – Accra, Ghana

Practical Information 

Certificate of Attendance
A Certificate of Attendance in PDF format was emailed to participants upon completion of the post-conference survey.
Language
The official conference language was English. Simultaneous translation was provided (French).
Disclaimer
This conference is intended for educational purposes only and aims to offer participants the opportunity to share information. The Organizing Secretariat of this conference, Virology Education, cannot accept any liability for the scientific content of the sessions or for any claims which may result from the use of information or publications from this conference. The Scientific Secretariat of this conference, the Amsterdam Institute for Global Health and Development, cannot accept any liability for the logistical arrangements made for this conference or any risks associated with them.
Insurance and Liability
This conference is intended for educational purposes only and aims to offer participants the opportunity to share information. It is highly recommended that all participants carry proper individual travel and health insurance, as Virology Education, AIGHD and the INTEREST conference cannot accept liability for accidents, illness, or injuries that may occur at or during the conference.
Photographs, audio, and video recording
Recording of official meeting sessions either via camera, smartphone, or other audio/video recording devices is not permitted without explicit consent of a speaker. Otherwise, only the official medical writers appointed by the INTEREST conference organisers may make recordings. Presentations will be posted on our INTEREST conference website as soon as possible after the conference if the speaker has given the organisers permission to do so.
Support
Endorsers
Language